Tirzepatide, the active GLP-1 ingredient in Mounjaro and Zepbound is having its moment in the sun. And for a while, as a result of the FDA shortage declaration for tirzepatide, these injections were available at established telehealth providers.
Unfortunately, the FDA semi-reversed its position on the tirzepatide shortage in mid-November, prompting major, reputable companies to cease offering tirzepatide injection treatments. (Henry does continue to offer oral tirzepatide programs, however.)
The FDA may still opt to continue the tirzepatide shortage in the coming months if conditions change. However, no safe, major companies are willing to risk fines and penalties to operate in gray areas. Instead, what you are likely seeing on Instagram and social media are ads by potentially illicit – but at the very least sketchy – companies willing to produce and distribute GLP1s they are essentially being told not to produce by their regulating body.
These are not the types of companies I feel comfortable recommending to strangers who will be injecting medicine in their arms. So please respect your body as much as I do and do not inject yourself with borderline bootleg tirzepatide shots being advertised at frequently unrealistic prices (that are often bait and switch anyway, if the product even shows up).
You can learn more about treatments that are available from real companies that follow FDA guidance and have long track records of providing safe and effective compounded GLP-1 treatments here. (And please do use our links to sign up if you do as that supports our site and helps us protect consumers from the bad actors in this space.)
